NCI-designated Consortium Cancer Center
|
|
|
WEEKLY RESEARCH NEWSLETTER
|
|
|
The Office of the Vice Chancellor for Health Sciences is delighted to host a series of guest lectures as part of the Moores Cancer Center Director recruitment effort. Each lecturer will highlight their personal achievements in education, research, and/or clinical care, as well as a brief vision for the Cancer Center.
|
|
|
|
Cathy Bradley, Ph.D., M.P.A.
Deputy Director
University of Colorado Cancer Center
June 14, 2022
8:00 a.m. - 9:00 a.m.
ACTRI Auditorium
in-person capacity limited to 60
The Seminar will also be via Zoom:
ZOOM MEETING LINK
|
|
|
|
Daphne Haas-Kogan, M.D.
Chair, Department of Radiation Oncology
Professor of Radiation Oncology
Harvard Medical School
June 16, 2022
5:00 p.m. - 6:00 p.m.
ACTRI Auditorium
in-person capacity limited to 60
The Seminar will also be via Zoom:
ZOOM MEETING LINK
|
|
|
| Robert Winn, M.D.
Director & Lipman Chair of Oncology
VCU Massey Cancer Center
June 27, 2022
5:00 p.m. - 6:00 p.m.
ACTRI Auditorium
in-person capacity limited to 60
The Seminar will also be via Zoom:
ZOOM MEETING LINK
|
|
|
| Nominate an Emerging Leader in IO
SITC is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award, one of the society's most prestigious opportunities for early career scientists.
The society is seeking the best and brightest to continue Dr. Rosenberg’s legacy with a research award for early career scientists focused on tackling challenges that face the field of cancer immunotherapy. Nominations are due July 15, 2022 and will be accepted via email to development@sitcancer.org.
|
|
|
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center
OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both MDs and PhDs and provides an intensive two-year period of research and training in the development of novel cancer therapeutics or diagnostics at the UCSD Moores Cancer Center. Trainees execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center while also participating in coursework, seminars, and lectures. The focus of the research may be basic, translational or clinical, but all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition into leadership roles in cancer therapeutics development in either an academic or industrial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure:
- See website for more details about CT2 program: WEBSITE
-
Complete CT2 program application (form available to download from the website above)
- Curriculum Vitae
- A one-page personal statement
- Proof of U.S. Citizenship/Residency
-
Three letters of recommendation (one from an identified mentor)
- Skills and Knowledge Required: PhD or MD degree, US Citizen or permanent resident status
For more information or to apply, please contact:
Amy Spilkin, Ph.D.
|
|
|
Moores Cancer Center Marketing & Communications Manager, Renee Maude, Elected to Public Affairs Marketing Network (PAMN) Steering Committee
In her new role, Renee will serve on the steering committee for two years alongside other elected members to plan and execute PAMN & NACCDO annual conferences, focusing on the upcoming conference on April 24-27, 2023 in Atlanta, GA.
|
| |
|
|
CCSG Solid Tumor Therapeutics Program
“The Role of the Low Molecular Weight Protein Tyrosine Phosphatase in Prostate Cancer”
July 13th, 2022
4:30pm – 5:30pm
Stephanie Stanford, Ph.D.
Assistant Professor, Department of Medicine
Laser Capture Microdissection Core Co-Director, UC San Diego
ZOOM MEETING LINK
|
|
|
CCSG Structural and Functional Genomics Cross Laboratory Meeting
June 22, 2022
12:00 p.m. - 1:00 p.m.
Shailja C. Shah, M.D., MPH
Division of Gastroenterology, UC San Diego
Staff Physician, GI Section, VA San Diego Healthcare System
|
|
|
Highlighted Funding Opportunity
|
|
|
Research Priority Area: Screening
Award: 5-year term with $1.2M total costs ($200K a year, plus 20% allowable indirect costs)
Detecting cancer early saves lives. Unfortunately, the important benefits of cancer screening are not reaching enough people. The purpose of this RFA is to fund innovative research that will facilitate more widespread cancer screening and early detection culminating in reduced cancer mortality.
Interdisciplinary Team Award: Funds team science to advance cancer screening and early detection. All Team Award applications must clearly articulate how the team will synergize to accelerate scientific advancement and clinical benefit.
LOI due to ACS on June 15, 2022. Application deadline if invited by ACS to apply, August 1, 2022
Research Scholar Grant: Up to 4 years, 165K/year
Application deadline: October 15, 2022
Clinician-Scientist Development Grant: 3-5 years, 135K/year
Application deadline: October 15, 2022
MORE INFO
|
|
|
Other Funding Opportunities
|
|
|
CA22-015 Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)
Award: $1.5M direct/yr for up to 5 years
To provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas.
Deadline: July 6, 2022
MORE INFO
|
Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
Award: via support from the FDA Center for Tobacco Products (CTP), intends to fund 8 TCORS, corresponding to a total of $32 million, for fiscal year 2023.
Future year amounts will depend on the availability of funds.
Deadline: July 14, 2022
MORE INFO
|
Breast Cancer Research Program: Transformative Breast Cancer Consortium Award.
The Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
Pre-Application Deadline: August 8, 2022
MORE INFO
|
CA22-017 Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
Award: Total $275,766 for Phase I awards, $1,838,436 for Phase II awards (NCI 2 years each)
To support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.
Deadline: August 22, 2022
MORE INFO
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups.
Deadline: September 6, 2022
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award:$500k direct/yr for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions to address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275k-unlimited direct costs 2-5 years, depending on mechanism
Component of the NCI's Informatics Technology for Cancer Research (ITCR) Program; focuses on the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
Breast Cancer Research Program: Anticipated Funding Opportunities. These BCRP awards will support innovative, high-impact research, with a mission of ending breast cancer for Service Members, Veterans, and the general public. Funding mechanisms will include Breakthrough Awards, Era of Hope Scholar Awards, and Innovator Awards.
MORE INFO
|
|
|
MCC’s Cancer Health Equity Collaborative (CHEC) Meeting
June 23, 2022
10:00 a.m. - 12:00 p.m.
-
Presentations from the California LGBTQ Health and Human Services Network on inclusive access to cancer care, Pfizer Oncology on diversity in clinical trials, as well as community partner updates.
If you’re interested in attending, please contact Valesca Largaespada.
|
|
|
New Developments in Precision Radiation Oncology & Radiogenomics Inaugural Symposium
June 16, 2022
8 a.m. - 6 p.m.
Keynote Speakers: Lawrence Marks, MD, UNC Chapel Hill and
Carmen Bergom, MD, PhD, Washington University School of Medicine in St. Louis
Location: The Alexandria at Torrey Pines Conference Center, La Jolla, CA
Contact: Ida Deichaite, Ph.D.
REGISTER HERE
|
|
|
|
October 11, 2022
Moores Cancer Center at UC San Diego Health
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
|
|
|
October 20-21, 2022
Time: TBD
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
- Recent breakthroughs in regenerative medicine
-
Stem cell regeneration in several disease areas
- Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Hosted by:
Catriona Jamieson, MD, Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center and Chief of the Division of Regenerative Medicine, and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Keynote Speakers:
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
MORE INFO
|
November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting & Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
REGISTER TODAY!
|
January 28, 2022
Prostate Cancer Patient Summit
|
|
|
Newly opened clinical trials (June 2022)
|
|
|
-
Research Grant Writer and Editor for the Gleiberman Head & Neck Cancer Center - #116068
-
[MULTIPLE POSTINGS] Pre-Award Fund Manager RA3 (remote or hybrid) - #116028
-
[MULTIPLE POSTINGS] Post-Award Fund Manager RA3 (remote or hybrid)- #115272
|
|
|
If you have newsworthy items to contribute, please contact our Marketing & Communications Manager, Renee Maude at amaude@health.ucsd.edu.
|
|
|
Moores Cancer Center is one of only 52 NCI-designated comprehensive cancer centers in the nation, and the only one providing multidisciplinary, research-driven detection, treatment, survivorship and prevention in the San Diego County region. The 360 member scientists and clinicians come from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities and pre-cancer and risk research, our researchers focus on translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. The Cancer Center was founded in 1978, the same year it received its NCI designation.
|
Research Administration Department
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
